Evidence map›Paper›PMID 26949512›Full record

ArticleCell & bioscience2016

Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant.

Ming-Chieh Yang, Andrew Yang, Jin Qiu, Benjamin Yang, Liangmei He, Ya-Chea Tsai, Jessica Jeang, T-C Wu, Chien-Fu Hung

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. A Genetically Modified attenuatedFrontiers in cellular and infection microbiology · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ming-Chieh YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan China.
Andrew YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
Jin QiuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Benjamin YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
Liangmei HeDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
Ya-Chea TsaiDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
Jessica JeangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
T-C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD USA.
Chien-Fu HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD USA ; Departments of Pathology and Oncology, The Johns Hopkins University School of Medicine, CRB II Room 307, 1550 Orleans Street, Baltimore, MD 21231 USA.
Johns Hopkins University · USJohns Hopkins Bayview Medical Center · USKaohsiung Veterans General Hospital · TW

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259
6 · The paper itself

Abstract

backgroundHuman Papillomavirus is responsible for over 99 % of cervical cancers and is associated with cancers of the head and neck. The currently available prophylactic vaccines against HPV do not generate therapeutic effects against established HPV infections and associated lesions and disease. Thus, the need for a therapeutic vaccine capable of treating HPV-induced malignancies persists. Synthetic long peptides vaccination is a popular antigen delivery method because of its safety, stability, production feasibility, and its need to be processed by professional antigen presenting cells before it can be presented to cytotoxic CD8+ T lymphocytes. Cancers in the buccal mucosa have been shown to elicit cancer-related inflammations that are capable of recruiting inflammatory and immune cells to generate antitumor effects. In the current study, we evaluated the therapeutic potential of synthetic HPV long peptide vaccination in the absence of adjuvant in the TC-1 buccal tumor model.

resultWe show that intratumoral vaccination with E7 long peptide alone effectively controls buccal TC-1 tumors in mice. Furthermore, we observed an increase in systemic as well as local E7-specific CD8+ T cells in buccal tumor-bearing mice following the vaccination. Finally, we show that induction of immune responses against buccal tumors by intratumoral E7 long peptide vaccination is independent of CD4+ T cells, and that the phenomenon may be related to the unique environment associated with mucosal tissues.

conclusionOur results suggest the possibility for clinical translation of the administration of adjuvant free therapeutic long peptide vaccine as a potentially effective and safe strategy for mucosal HPV-associated tumor treatment.

Indexed as

Adjuvant freeBuccal tumorE7 long peptideImmunotherapy

Identifiers

PMID26949512
PMCPMC4778350
OpenAlexW2288541552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.